Arvinas, Inc. (ARVN): Net Income
-$80.80M
Year ended 2025-12-31
$9.30M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$80.80M | n/m | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | -$198.90M | n/m | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | -$367.30M | n/m | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | -$282.50M | n/m | 2025-02-11, From 2022-01-01 |
| 2021-12-31 | -$191.00M | n/m | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | -$119.30M | n/m | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | -$70.30M | n/m | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | -$41.48M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | -$24.05M | n/a | 2019-03-26, From 2017-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Arvinas, Inc. (ARVN) | 2025-12-31 | -$80.80M | n/m |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $124.45M | n/m |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | -$68.11M | n/m |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | -$103.27M | n/m |
| Harrow, Inc. (HROW) | 2025-12-31 | -$5.14M | n/m |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | -$353.00M | n/m |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $87.01M | n/m |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $554.0K | n/m |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | -$5.34M | n/m |
Compare ARVN, LGND, VREOF, SDGR side by side · Screen every company in Pharmaceutical Preparations ↗